received regulatory clearance for a clot-removing device, sending its shares higher Wednesday.
The device, dubbed the AngioJet Xpeedior catheter, was approved by the Food and Drug Administration for the removal of blood clots in the upper and lower extremities. The Xpeedior is the first approved device for use in thrombectomies in peripheral veins, the company says.
The stock was up 9.2% to $12.46.
Each year, 600,000 patients are diagnosed with a condition known as deep vein thrombosis, which can lead to limb loss and even death, Possis says. In addition, each year, approximately 200,000 people die from pulmonary embolism, which occurs when a clot is dislodged from a vein and migrates to the lungs, blocking blood flow.
Until now, most treatments for blood clots have been anticoagulant drugs, which can take weeks to be effective.